 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || J2H-1702 / J2HBiotech
P1 data, Journal: First in human randomised trial of J2H-1702: A novel 11?-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment. (Pubmed Central) - Sep 25, 2023
The results of this study suggest that J2H-1702 could be developed as an effective therapeutic option for NASH.
- | J2H-1702 / J2HBiotech
Journal: Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH. (Pubmed Central) - Nov 30, 2022
Of great interest, the 11βHSD1 inhibitor J2H-1702 significantly attenuated hepatic lipid accumulation and ameliorated liver fibrosis in diet- and toxicity-induced NASH mouse models. Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH.
- J2H-1702 / J2HBiotech
Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1123;
Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH. Together, our data indicate that J2H-1702 is a promising new clinical candidate for the treatment of NASH.